论文部分内容阅读
齐多夫定(Zidovudine)对人Ⅰ型免疫缺陷病毒(HIV)感染有效,能明显延长存活时间;但有严重毒副作用,特别是骨髓抑制。 866例中,艾滋病500例,与艾滋病有关的综合征(CD_4~+淋巴细胞数≤0.25×10~9/L)366例。诊断后平均116日(中数51日)开始齐多夫定治疗;84％患者用200 mg每日6次,11％患者用100 mg每日6次。随访2年。减量至少一次者114例(13％),停药至少一次者602例(70%)。首次停药在治疗的106～714日,平均持续30日。减量或停药
Zidovudine is effective against human immunodeficiency virus type 1 (HIV) infection and significantly prolongs survival time; however, it has serious side effects, particularly myelosuppression. In 866 cases, there were 500 cases of AIDS and 366 cases of AIDS-related syndrome (the number of CD 4 + lymphocytes ≤ 0.25 × 10 ~ 9 / L). Zidovudine treatment started 116 days after the diagnosis (median 51); 84% had 200 mg 6 times daily and 11% had 100 mg 6 times daily. Follow up for 2 years. 114 cases (13%) had at least one reduction, and 602 cases (70%) stopped at least once. The first withdrawal in the treatment of 106 to 714 days, an average of 30 days. Reduction or withdrawal